

## Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2025

[Japanese GAAP]

Company name: NIHON TRIM CO., LTD.

Listing: Tokyo Stock Exchange

Securities code: 6788

URL: <https://www.nihon-trim.co.jp/>

Representative: Norio Tahara, President

Contact: Yasuhiro Daikoku, Senior Managing Executive Officer and General Manager of Administration  
Division

Tel: +81-(0) 6-6456-4600

Scheduled date of Annual General Meeting of Shareholders: June 24, 2025

Scheduled date of filing of Annual Securities Report: June 23, 2025

Scheduled date of dividend payment: June 25, 2025

Supplementary materials for financial results: Yes

Holding of financial results meeting: Yes (for institutional investors)

(All amounts are rounded down to the nearest million yen)

### 1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (April 1, 2024 - March 31, 2025)

#### (1) Consolidated results of operations

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal year ended Mar. 31, 2025	22,463	10.0	3,285	6.7	3,535	9.5	2,241	4.2
Fiscal year ended Mar. 31, 2024	20,414	13.7	3,080	29.5	3,227	28.3	2,150	30.6

Note: Comprehensive income (million yen) Fiscal year ended Mar. 31, 2025: 2,584 (up 4.6%)

Fiscal year ended Mar. 31, 2024: 2,470 (up 35.7%)

	Net income per share	Diluted net income per share	Return on equity	Ordinary profit on total assets	Operating profit on net sales
	Yen	Yen	%	%	%
Fiscal year ended Mar. 31, 2025	292.41	—	9.7	10.6	14.6
Fiscal year ended Mar. 31, 2024	280.51	—	9.9	10.7	15.1

Reference: Investment gain (loss) by equity method (million yen) Fiscal year ended Mar. 31, 2025: 2

Fiscal year ended Mar. 31, 2024: 2

#### (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of Mar. 31, 2025	35,353	25,546	67.8	3,125.80
As of Mar. 31, 2024	31,544	23,627	70.7	2,911.21

Reference: Shareholders' equity (million yen) As of Mar. 31, 2025: 23,967 As of Mar. 31, 2024: 22,314

#### (3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Million yen	Million yen	Million yen	Million yen
Fiscal year ended Mar. 31, 2025	2,675	(1,887)	552	15,394
Fiscal year ended Mar. 31, 2024	2,973	(882)	(998)	13,959

### 2. Dividends

	Dividend per share					Total dividends	Dividend payout ratio (consolidated)	Dividend on equity (consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
Fiscal year ended Mar. 31, 2024	—	0.00	—	85.00	85.00	688	30.3	3.0
Fiscal year ended Mar. 31, 2025	—	0.00	—	130.00	130.00	1,077	44.5	4.3
Fiscal year ending Mar. 31, 2026 (forecasts)	—	0.00	—	130.00	130.00		42.7	

### 3. Consolidated Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 - March 31, 2026)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	12,500	10.0	1,750	(5.7)	1,830	(6.1)	1,180	(9.7)	156.35
Full year	25,000	11.3	3,540	7.7	3,700	4.7	2,300	2.6	304.74

**\* Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly added: –

Excluded: –

(2) Changes in accounting policies and accounting estimates, and restatements

(i) Changes in accounting policies due to revisions in accounting standards, others: None

(ii) Changes in accounting policies other than (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(3) Number of outstanding shares (common shares)

(i) Number of shares issued at end of period (including treasury shares)

As of Mar. 31, 2025: 8,656,780 shares

As of Mar. 31, 2024: 8,656,780 shares

(ii) Number of treasury shares at end of period

As of Mar. 31, 2025: 989,256 shares

As of Mar. 31, 2024: 991,758 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended Mar. 31, 2025: 7,665,202 shares

Fiscal year ended Mar. 31, 2024: 7,665,091 shares

Note: The Company has adopted the Employee Stock Ownership Plan (J-ESOP) and the Trust-Type Employee Shareholding Incentive Plan (E-Ship). The company shares held by these trusts are included in the number of treasury shares, which are to be deducted from the calculation of the number of treasury shares at end of period and the average number of shares outstanding during the period.

\* The current financial report is not subject to audit by certified public accountants or auditing firms.

\* Cautionary statement with respect to forward-looking statements, and other special items

Earnings forecasts regarding future performance in this material are based on assumptions judged to be valid and information currently available to the Company, and the Company does not in any way guarantee the achievement of the forecasts. Actual results may differ significantly from these forecasts for a number of factors. Please refer to “1. Overview of Results of Operations, etc., (4) Future Outlook” on page 5 of the attachments for assumptions for forecasts and notes of caution for usage.

**Contents of Attachments**

1. Overview of Results of Operations, etc.	2
(1) Overview of Results of Operations for the Current Fiscal Year	2
(2) Overview of Financial Position for the Current Fiscal Year	4
(3) Overview of Cash Flows for the Current Fiscal Year	4
(4) Future Outlook	5
2. Basic Approach for the Selection of Accounting Standards	6
3. Consolidated Financial Statements and Notes	7
(1) Consolidated Balance Sheet	7
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income	9
Consolidated Statement of Income	9
Consolidated Statement of Comprehensive Income	10
(3) Consolidated Statement of Changes in Equity	11
(4) Consolidated Statement of Cash Flows	13
(5) Notes to Consolidated Financial Statements	15
Assumption for Going Concern	15
Business Combinations	15
Segment and Other Information	15
Per Share Information	17
Subsequent Events	17

## 1. Overview of Results of Operations, etc.

### (1) Overview of Results of Operations for the Current Fiscal Year

The Nihon Trim Group (“the Group”) is committed to “contributing to the creation of healthy and comfortable lives” under its corporate philosophy. To this end, the Group operates its business under the main theme of health and medical care. The Group’s mission is to contribute to people’s well-being through its businesses including Electrolyzed Hydrogen Water (EHW), electrolyzed water hemodialysis, and regenerative medicine. Under the slogan “Society will always need our products, at any point in time,” the Group will contribute to the realization of a sustainable society and achieve sustainable enhancement of its corporate and shareholder value.

During the current fiscal year, the Group’s net sales increased 10.0% year on year to 22,463 million yen, operating profit increased 6.7% to 3,285 million yen, ordinary profit increased 9.5% to 3,535 million yen, and profit attributable to owners of parent increased 4.2% to 2,241 million yen.

Net sales, operating profit, and ordinary profit all reached record highs, making this a year that will lead to further growth in the Electrolyzed Hydrogen Water (EHW) apparatus sales division and each Group company in the coming fiscal years.

We had originally set a target of 32,000 million yen in consolidated net sales for the fiscal year ending March 31, 2027. However, after analyzing the current status of our EHW apparatus sales and each Group company, and reassessing our future objectives and the measures needed to achieve them, we have formulated a new medium-term management plan targeting 31,000 million yen in consolidated net sales for the fiscal year ending March 31, 2028. For an overview of the medium-term management plan, please refer to the Supplementary Material for Results of Operations released today.

For the fiscal year ending March 31, 2026, which marks the first year of the medium-term management plan, we plan to achieve record highs in all net sales, operating profit, and ordinary profit, with net sales of 25,000 million yen (up 11.3% year on year), operating profit of 3,540 million yen (up 7.7% year on year), ordinary profit of 3,700 million yen (up 4.7% year on year), and profit attributable to owners of parent of 2,300 million yen (up 2.6% year on year).

The Company’s basic capital policy is to aim for a sustainable increase in shareholder value by achieving a solid balance of capital efficiency, shareholder returns and financial soundness. As announced on February 13, 2025, we have decided to raise the DOE (dividend on equity ratio) from 3%, the baseline for shareholder returns, to 4%, and have raised the dividend forecast for the fiscal year ended March 31, 2025 of 95 yen per share with an increase of 35 yen to 130 yen. As a result, the DOE for the fiscal year ended March 31, 2025 reached 4.3%, with a dividend payout ratio of 44.5%.

Furthermore, at a meeting of the Board of Directors held today, we resolved matters related to the acquisition of treasury shares in order to enhance shareholder returns and improve capital efficiency as part of our capital policy. For details, please refer to the “Notice Regarding Decision on Matters Related to Acquisition of Treasury Shares” released today.

Results by business segment were as follows.

#### Water Healthcare Business

In the EHW apparatus sales business in Japan, net sales of EHW apparatus for the current fiscal year increased 0.6% year on year to 9,077 million yen.

In the direct sales division, which primarily focuses on workplace sales, net sales increased 4.4% year on year to 8,056 million yen. Alongside an increase in the number of seminars held, the development of new channels in the sports and beauty care fields continued to progress favorably. Although the recruitment of sales personnel, which we have been focusing on since the previous fiscal year, has not yet reached target levels, progress has been made on the recruitment of new personnel that satisfy the Company’s requirements by strengthening partnerships with recruiting companies, and we will continue to focus on this initiative. In addition, efforts to enhance sales capabilities have yielded measurable improvements in sales efficiency.

In the Wholesale division (wholesale and OEM), net sales decreased 21.5% year on year to 1,020 million yen.

This year-on-year decrease is attributable to a significant increase in the number of shipments in the previous fiscal year due to rush demand from existing OEM partners in advance of the price revisions, and to the time required during the current fiscal year to develop new OEM partners and overseas agents. However, negotiations for acquiring new agents are progressing steadily, and we are looking to expand both domestically and internationally in the future.

With regard to sales of water purification cartridges in Japan, which generate a consistent revenue stream once an EHW apparatus is installed, net sales increased 4.8% to 5,602 million yen, showing steady growth. We will continue to strengthen customer service, including regular information distribution and follow-up by telephone, aiming to maintain and expand a stable revenue base.

Overseas, PT. SUPER WAHANA TEHNO, which operates a bottled water business in Indonesia, grew significantly with net sales of 3,704 million yen (up 63.4% year on year), reaching a new record high. This strong performance was driven by enhanced marketing measures, including a reinforced TV commercial campaign launched in the previous fiscal year to boost brand awareness of Pristine, as well as advertisements on social networking services leveraging influencers and the execution of large-scale events. We are steadily progressing toward achieving 1 trillion rupiah (9,000 million yen, 1 rupiah = 0.0090 yen) in net sales, a target shared with the Sinar Mas Group, a local partner.

In the field of research and development, we have continuously worked on research aimed at identifying the mechanism for the benefits of EHW as well as looking for new business seeds jointly with RIKEN, Tohoku University, Waseda University, Tokai University, and others, such as “Essential Health Care Science Collaborative Research Course” with Kobe University. Four papers are currently in the process of being submitted and we are preparing to submit two more in the near future.

On the other hand, in regard to the joint paper with the University of Tokyo on new electrocatalysts that we released in October of last year, in addition to the development of new products, we are working on the practical application of this research in high-efficiency hydrogen production technology with an eye toward business development in the energy field (printed in the Journal of Materials Chemistry A, a journal of the Royal Society of Chemistry).

As a result of the above, the water healthcare business recorded net sales of 19,565 million yen (up 10.1% year on year), with segment profit of 2,895 million yen (up 7.7% year on year).

## Medical Business

In the electrolyzed water hemodialysis (\*1) business, net sales increased 79.2% year on year to 108 million yen as a result of introduction at three facilities in this fiscal year. The number of facilities that have adopted electrolyzed water hemodialysis has reached 34 facilities with 1,030 beds, and approximately 3,000 dialysis patients are currently receiving electrolyzed water hemodialysis. Okamura Medical Corporation Nephrology and Urology Clinic, which adopted electrolyzed water hemodialysis during this fiscal year, began a new effort to introduce electrolyzed water hemodialysis for overnight dialysis (\*2) for the first time in Japan. This development is expected to further improve the quality of life (QOL) for dialysis patients.

We take pride in our electrolyzed water hemodialysis, a revolutionary technology that can significantly enhance the well-being of dialysis patients. We have thus strengthened our efforts to collect evidence and improve dialysis machines, aiming to expand their use as a next generation therapy that sets the global standard for dialysis treatment. We will continue focusing on building foundations for the widespread use of electrolyzed water hemodialysis. Specifically, we are working on expanding the fields of activities to raise awareness by holding seminars, including nephrology conferences, at organizations around the country such as the Association for Clinical Engineers and by other means. We are also seeking new contract opportunities by bolstering cooperation with agencies, and engaged in public relations activities to raise awareness of electrolyzed water hemodialysis among dialysis patients.

(\*1) Electrolyzed water hemodialysis offers a next-generation of new dialysis treatment using electrolyzed RO water containing dissolved hydrogen, which is produced by our technology, to dilute dialysate. It is unconventional technology that focuses attention on the functions of water as a solvent for the first time in the world. We obtained data that showed that electrolyzed water hemodialysis reduced the dosage of drugs and the complication rate and annual crude death rate (CDR) of patients compared to traditional hemodialysis, which has drawn attention.

- (\*2) Overnight dialysis refers to extended dialysis performed during nighttime sleep hours. By conducting dialysis over 8 to 10 hours at a slower pace, it enables more effective removal of uremic toxins and reduces physical burden, offering numerous benefits such as alleviation of post-dialysis fatigue and a lower risk of complications.

In the field of regenerative medicine, StemCell Institute Inc. (listed on TSE Growth Market, Securities Code: 7096, our share: 70.5%) achieved a new record high in revenue. The company published its earnings results for the fiscal year ended March 31, 2025, on May 13 this year, the same date as did the Group. For details, please refer to the StemCell Institute's Summary of Financial Results for the Fiscal Year Ended March 31, 2025.

As a result of the above, the medical business recorded net sales of 2,898 million yen (up 9.9% year on year) with segment profit of 389 million yen (down 0.7% year on year).

## **(2) Overview of Financial Position for the Current Fiscal Year**

Total assets increased 3,809 million yen, or 12.1%, from the end of the previous fiscal year to 35,353 million yen at the end of the current fiscal year on a consolidated basis.

### **(i) Assets**

Current assets increased 1,830 million yen, or 8.0%, from the end of the previous fiscal year to 24,750 million yen. The main factors were increases in cash and deposits of 1,435 million yen and notes and accounts receivable-trade of 585 million yen, despite a decrease in securities of 301 million yen.

Non-current assets increased 1,978 million yen, or 22.9%, from the end of the previous fiscal year to 10,603 million yen. The main factors were increases in long-term time deposits of 1,500 million yen, saving-type insurance premiums included in other under investments and other assets of 674 million yen, and land of 403 million yen, despite a decrease in investment securities of 460 million yen.

### **(ii) Liabilities**

Current liabilities increased 524 million yen, or 7.9%, from the end of the previous fiscal year to 7,155 million yen. The main factors were increases in accounts payable-other included in other under current liabilities of 342 million yen and advances received of 370 million yen, despite a decrease in income taxes payable of 208 million yen.

Non-current liabilities increased 1,365 million yen, or 106.1%, from the end of the previous fiscal year to 2,652 million yen. The main factor was an increase in long-term borrowings of 1,131 million yen.

### **(iii) Net assets**

Net assets increased 1,918 million yen, or 8.1%, from the end of the previous fiscal year to 25,546 million yen. The main factors were the recognition of profit attributable to owners of parent of 2,241 million yen and an increase in non-controlling interests of 266 million yen, which were partially offset by a decrease resulting from dividend payments of 688 million yen.

## **(3) Overview of Cash Flows for the Current Fiscal Year**

Cash and cash equivalents (hereinafter "net cash") increased 1,435 million yen from the end of the previous fiscal year to 15,394 million yen at the end of the current fiscal year on a consolidated basis.

### **Cash flows from operating activities**

Net cash provided by operating activities was 2,675 million yen (2,973 million yen provided in the previous fiscal year).

The main factors include profit before income taxes of 3,470 million yen, depreciation of 471 million yen, and a 369 million yen increase in advances received, which were partially offset by a 569 million yen increase in trade receivables and income taxes paid of 1,216 million yen.

### **Cash flows from investing activities**

Net cash used in investing activities was 1,887 million yen (882 million yen used in the previous fiscal year).

The main factors were payments into time deposits of 1,500 million yen, purchase of investment securities of 932

million yen, purchase of property, plant and equipment of 759 million yen, and purchase of insurance funds of 786 million yen, which were partially offset by proceeds from withdrawal of time deposits of 500 million yen, proceeds from redemption of securities of 1,300 million yen, and proceeds from sales of investment securities of 203 million yen.

#### Cash flows from financing activities

Net cash provided by financed activities was 552 million yen (998 million yen used in the previous fiscal year).

The main factors were proceeds from long-term borrowings of 1,211 million yen, proceeds from disposal of treasury shares of 710 million yen, and proceeds from sale of shares of subsidiaries not resulting in change in scope of consolidation of 234 million yen, which were partially offset by purchase of treasury shares of 701 million yen and dividends paid of 687 million yen.

#### Reference: Trends in Cash flow indicators

	FY3/21	FY3/22	FY3/23	FY3/24	FY3/25
Shareholders' equity ratio	69.8	74.5	72.4	70.7	67.8
Shareholders' equity ratio based on market value	128.0	74.2	80.0	98.4	83.6
Debt repayment period (years)	0.4	0.0	0.0	0.0	0.4

Notes: Shareholders' equity ratio: Shareholders' equity / Total assets  
 Shareholders' equity ratio based on market value: Market capitalization / Total assets  
 Debt repayment period: Interest-bearing debt / Operating cash flows

- \* All indicators are calculated based on consolidated figures.
- \* Market capitalization is calculated by multiplying the closing price at the end of period by the number of shares outstanding at the end of period (excluding treasury stock).
- \* Operating cash flows are the figures for operating cash flows in the consolidated statement of cash flows. Interest-bearing debt includes all debt on the consolidated balance sheet that incurs interest.
- \* Disclosure of interest coverage ratio (operating cash flows / interest payments) is omitted because the amount of interest payments is insignificant.

#### (4) Future Outlook

The Group has formulated a new medium-term management plan of 31,000 million yen in consolidated net sales for the fiscal year ending March 31, 2028, and will continue to make forward-looking investments from a medium- to long-term perspective in order to achieve sustainable growth and increase corporate value by contributing to the achievement of Sustainable Development Goals (SDGs) through our business as well as further business expansion.

With regard to the consolidated forecast for the fiscal year ending March 31, 2026, we plan to achieve record highs in net sales, operating profit, and ordinary profit, with net sales of 25,000 million yen (up 11.3% year on year), operating profit of 3,540 million yen (up 7.7% year on year), ordinary profit of 3,700 million yen (up 4.7% year on year), and profit attributable to owners of parent of 2,300 million yen (up 2.6% year on year).

Forecasts by business segment are as follows.

#### Water Healthcare Business

In the EHW apparatus sales business, growing awareness of health and beauty driven by the recent intestinal health boom, along with increasing concerns over water safety due to water pollution in certain regions resulting from organic fluorine compounds (PFOS and PFOA), have brought greater attention to the “quality” of water. Our EHW apparatus is classified as a controlled medical device that has been approved for its effects on improvement of gastrointestinal conditions. In addition, the activated carbon filters used in our cartridges can effectively filter out certain organic fluorine compounds, and as such, we anticipate further growth in demand for EHW apparatus. In the direct sales division, we will continue initiatives with a medium- to long-term perspective, focusing on workplace sales. The initiatives include recruiting sales personnel, enhancing sales capabilities, further developing the sports and beauty care fields, and cultivating new sales channels. In the Wholesale division, we will strengthen sales support for existing domestic agents while actively working to acquire new major agents. Overseas, in addition to our current presence in Vietnam, and Hong Kong, we are preparing to expand into several other countries, primarily in the Asia region, and are making dedicated efforts toward realizing this expansion.

With regard to sales of water purification cartridges, which generate a consistent revenue stream once an EHW apparatus is installed, we expect continuous stable sales growth in the next fiscal year.

For a bottled water business in Indonesia, we will further strengthen our advertising and marketing measures in fiscal 2025, with an eye toward achieving the target of 1 trillion rupiah (9,000 million yen, 1 rupiah = 0.0090 yen) in net sales in fiscal 2034. In addition, we are discussing the new construction of our own factories in collaboration with our local partner Sinar Mas Group. In response to growing demand, we aim to strengthen production capability and increase efficiency to establish a stable supply system.

Based on the above, for the fiscal year ending March 31, 2026, we plan to increase both sales and profit in the water healthcare business, with net sales of 21,700million yen (up 10.9% year on year) and segment profit of 3,090 million yen (up 6.7% year on year).

## **Medical Business**

In the electrolyzed water hemodialysis business, we anticipate the introduction of the system at six new facilities in the fiscal year ending March 31, 2026. We will seek new candidates for introduction by actively participating in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy to be held in June this year and other academic conferences organized by various dialysis-related organizations, such as the Japanese Society of Renal Failure Complications and the Association of Electrolyzed Water-Hemodialysis (EW-HD) Study Group. We will continue to strengthen our efforts to collect evidence and improve dialysis machines, aiming to expand their use as the next generation of global standard therapy.

In the field of regenerative medicine, StemCell Institute plans to achieve record-high earnings in the next fiscal year by further expanding its existing business and vigorously developing new businesses. The company published its earnings forecast for the fiscal year ending March 31, 2026, on May 13 this year, the same date as did the Group. For details, please refer to the StemCell Institute's Summary of Financial Results.

Through the efforts mentioned above, for the fiscal year ending March 31, 2026, we plan to increase both sales and profit in medical business, with net sales of 3,300 million yen (up 13.9% year on year) and segment profit of 450 million yen (up 15.4% year on year).

## **2. Basic Approach for the Selection of Accounting Standards**

The Group will continue to prepare consolidated financial statements using Generally Accepted Accounting Principles in Japan for the time being to permit comparisons with prior years and with the financial data of other companies. We will take suitable actions with regard to the application of International Financial Reporting Standards (IFRS) by taking into account associated factors in Japan and other countries.



**3. Consolidated Financial Statements and Notes****(1) Consolidated Balance Sheet**

	(Thousands of yen)	
	FY3/24	FY3/25
	(As of Mar. 31, 2024)	(As of Mar. 31, 2025)
Assets		
Current assets		
Cash and deposits	13,959,093	15,394,490
Notes and accounts receivable-trade	5,758,101	6,343,591
Securities	1,302,898	1,001,865
Finished goods	604,471	627,719
Raw materials and supplies	1,064,684	1,104,771
Other	255,646	304,347
Allowance for doubtful accounts	(25,056)	(26,437)
Total current assets	22,919,840	24,750,348
Non-current assets		
Property, plant and equipment		
Buildings and structures	2,444,567	2,577,374
Accumulated depreciation	(1,366,194)	(1,457,752)
Buildings and structures, net	1,078,373	1,119,622
Land	2,579,253	2,983,117
Other	2,541,806	2,825,928
Accumulated depreciation	(1,768,831)	(1,941,325)
Other, net	772,974	884,602
Total property, plant and equipment	4,430,601	4,987,342
Intangible assets		
Goodwill	348,910	311,791
Other	243,763	318,356
Total intangible assets	592,674	630,147
Investments and other assets		
Investment securities	1,767,309	1,306,584
Deferred tax assets	420,258	487,909
Long-term time deposits	—	1,500,000
Other	1,463,189	1,740,947
Allowance for doubtful accounts	(49,113)	(49,500)
Total investments and other assets	3,601,644	4,985,940
Total non-current assets	8,624,920	10,603,431
Total assets	31,544,761	35,353,779

	(Thousands of yen)	
	FY3/24	FY3/25
	(As of Mar. 31, 2024)	(As of Mar. 31, 2025)
Liabilities		
Current liabilities		
Accounts payable-trade	550,221	589,774
Current portion of long-term borrowings	—	62,568
Income taxes payable	740,198	532,132
Advances received	3,702,438	4,072,488
Provision for bonuses	185,000	200,425
Provision for product warranties	84,000	85,000
Other	1,368,342	1,612,642
Total current liabilities	6,630,202	7,155,031
Non-current liabilities		
Long-term borrowings	—	1,131,089
Provision for share-based payments	88,800	177,454
Provision for retirement benefits for directors (and other officers)	299,572	260,406
Retirement benefit liability	407,417	367,842
Asset retirement obligations	56,079	64,192
Other	435,342	651,593
Total non-current liabilities	1,287,211	2,652,578
Total liabilities	7,917,414	9,807,610
Net assets		
Shareholders' equity		
Share capital	992,597	992,597
Capital surplus	1,823,945	1,864,182
Retained earnings	22,838,855	24,391,935
Treasury shares	(3,448,320)	(3,408,285)
Total shareholders' equity	22,207,077	23,840,429
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	64,947	(14,881)
Foreign currency translation adjustment	49,075	108,612
Remeasurements of defined benefit plans	(6,603)	33,004
Total accumulated other comprehensive income	107,420	126,735
Non-controlling interests	1,312,848	1,579,004
Total net assets	23,627,347	25,546,169
Total liabilities and net assets	31,544,761	35,353,779

**(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income****Consolidated Statement of Income**

(Thousands of yen)

	FY3/24 (Apr. 1, 2023 - Mar. 31, 2024)	FY3/25 (Apr. 1, 2024 - Mar. 31, 2025)
Net sales	20,414,865	22,463,830
Cost of sales	6,194,668	7,027,368
Gross profit	14,220,196	15,436,462
Selling, general and administrative expenses	11,139,709	12,150,825
Operating profit	3,080,486	3,285,636
Non-operating income		
Interest income	30,310	56,756
Dividend income	480	245
Commission income	1,711	1,239
Share of profit of entities accounted for using equity method	2,488	2,000
Rental income from real estate	82,625	84,016
Foreign exchange gains	3,701	7,529
Surrender value of insurance policies	5,305	59,371
Subsidy income	1,349	—
Gain on sale of non-current assets	34,195	38,678
Other	19,976	21,545
Total non-operating income	182,144	271,382
Non-operating expenses		
Interest expenses	2,206	2,310
Depreciation of assets for rent	14,436	14,994
Provision of allowance for doubtful accounts	300	300
Loss on cancellation of insurance policies	4,758	—
Other	13,747	4,138
Total non-operating expenses	35,448	21,742
Ordinary profit	3,227,183	3,535,276
Extraordinary income		
Gain on sale of non-current assets	1,992	—
Gain on sale of investment securities	22,327	149,274
Gain on reversal of office transfer expenses	1,746	—
Total extraordinary income	26,066	149,274
Extraordinary losses		
Loss on valuation of shares of subsidiaries and associates	—	214,134
Total extraordinary losses	—	214,134
Profit before income taxes	3,253,249	3,470,416
Income taxes-current	1,025,197	953,815
Income taxes-deferred	(76,865)	(36,776)
Total income taxes	948,332	917,039
Profit	2,304,917	2,553,377
Profit attributable to non-controlling interests	154,774	311,974
Profit attributable to owners of parent	2,150,143	2,241,402

**Consolidated Statement of Comprehensive Income**

(Thousands of yen)

	FY3/24	FY3/25
	(Apr. 1, 2023 - Mar. 31, 2024)	(Apr. 1, 2024 - Mar. 31, 2025)
Profit	2,304,917	2,553,377
Other comprehensive income		
Valuation difference on available-for-sale securities	86,991	(107,869)
Foreign currency translation adjustment	83,878	97,017
Remeasurements of defined benefit plans, net of tax	(5,632)	41,325
Share of other comprehensive income of entities accounted for using equity method	619	649
Total other comprehensive income	165,856	31,123
Comprehensive income	2,470,774	2,584,501
Comprehensive income attributable to:		
Owners of parent	2,258,121	2,260,718
Non-controlling interests	212,652	323,782

**(3) Consolidated Statement of Changes in Equity**

FY3/24 (Apr. 1, 2023 - Mar. 31, 2024)

(Thousands of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	992,597	1,823,945	21,660,473	(3,448,032)	21,028,983
Changes during period					
Dividends of surplus			(971,761)		(971,761)
Profit attributable to owners of parent			2,150,143		2,150,143
Purchase of treasury shares				(287)	(287)
Disposal of treasury shares					–
Purchase of shares of consolidated subsidiaries					–
Sale of shares of consolidated subsidiaries					–
Net changes in items other than shareholders' equity					
Total changes during period	–	–	1,178,382	(287)	1,178,094
Balance at end of period	992,597	1,823,945	22,838,855	(3,448,320)	22,207,077

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	1,159	(89)	(1,627)	(557)	1,100,196	22,128,622
Changes during period						
Dividends of surplus						(971,761)
Profit attributable to owners of parent						2,150,143
Purchase of treasury shares						(287)
Disposal of treasury shares						–
Purchase of shares of consolidated subsidiaries						–
Sale of shares of consolidated subsidiaries						–
Net changes in items other than shareholders' equity	63,788	49,165	(4,975)	107,978	212,652	320,630
Total changes during period	63,788	49,165	(4,975)	107,978	212,652	1,498,724
Balance at end of period	64,947	49,075	(6,603)	107,420	1,312,848	23,627,347

FY3/25 (Apr. 1, 2024 - Mar. 31, 2025)

(Thousands of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	992,597	1,823,945	22,838,855	(3,448,320)	22,207,077
Changes during period					
Dividends of surplus			(688,323)		(688,323)
Profit attributable to owners of parent			2,241,402		2,241,402
Purchase of treasury shares				(701,291)	(701,291)
Disposal of treasury shares		(30,778)		741,326	710,548
Purchase of shares of consolidated subsidiaries		(53,836)			(53,836)
Sale of shares of consolidated subsidiaries		124,851			124,851
Net changes in items other than shareholders' equity					
Total changes during period	–	40,236	1,553,079	40,035	1,633,351
Balance at end of period	992,597	1,864,182	24,391,935	(3,408,285)	23,840,429

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	64,947	49,075	(6,603)	107,420	1,312,848	23,627,347
Changes during period						
Dividends of surplus						(688,323)
Profit attributable to owners of parent						2,241,402
Purchase of treasury shares						(701,291)
Disposal of treasury shares						710,548
Purchase of shares of consolidated subsidiaries					(40,201)	(94,038)
Sale of shares of consolidated subsidiaries					54,133	178,984
Net changes in items other than shareholders' equity	(79,829)	59,536	39,607	19,315	252,223	271,539
Total changes during period	(79,829)	59,536	39,607	19,315	266,155	1,918,822
Balance at end of period	(14,881)	108,612	33,004	126,735	1,579,004	25,546,169

**(4) Consolidated Statement of Cash Flows**

	(Thousands of yen)	
	FY3/24	FY3/25
	(Apr. 1, 2023 - Mar. 31, 2024)	(Apr. 1, 2024 - Mar. 31, 2025)
Cash flows from operating activities		
Profit before income taxes	3,253,249	3,470,416
Depreciation	440,426	471,446
Amortization of goodwill	37,119	37,119
Increase (decrease) in allowance for doubtful accounts	(2,517)	1,638
Increase (decrease) in provision for bonuses	6,542	15,424
Increase (decrease) in provision for share-based payments	88,800	88,654
Increase (decrease) in retirement benefit liability	36,554	17,079
Increase (decrease) in provision for retirement benefits for directors (and other officers)	19,412	(39,166)
Interest and dividend income	(30,790)	(57,001)
Interest expenses	2,206	2,310
Share of loss (profit) of entities accounted for using equity method	(2,488)	(2,000)
Loss (gain) on sale of investment securities	(22,327)	(149,274)
Loss (gain) on cancellation of insurance policies	(547)	(59,371)
Loss on valuation of shares of subsidiaries and associates	—	214,134
Subsidy income	(1,349)	—
Decrease (increase) in trade receivables	(578,243)	(569,224)
Decrease (increase) in inventories	(80,915)	(37,073)
Increase (decrease) in trade payables	13,424	26,950
Increase (decrease) in advances received	368,125	369,774
Increase (decrease) in accrued consumption taxes	11,718	(104,740)
Other, net	209,485	135,771
Subtotal	3,767,884	3,832,868
Interest and dividends received	40,003	61,741
Subsidies received	1,349	—
Interest paid	(2,206)	(2,310)
Income taxes paid	(833,401)	(1,216,941)
Net cash provided by (used in) operating activities	2,973,629	2,675,358
Cash flows from investing activities		
Payments into time deposits	(500,000)	(1,500,000)
Proceeds from withdrawal of time deposits	—	500,000
Proceeds from redemption of securities	—	1,300,000
Purchase of property, plant and equipment	(386,049)	(759,901)
Proceeds from sale of property, plant and equipment	38,252	38,678
Purchase of intangible assets	(46,482)	(158,761)
Purchase of shares of subsidiaries and associates	—	(34,461)
Purchase of investment securities	(199,900)	(932,172)
Proceeds from sales of investment securities	72,327	203,024
Payments of leasehold and guarantee deposits	(7,854)	(17,663)
Proceeds from refund of leasehold and guarantee deposits	28,932	3,011
Purchase of insurance funds	(29,520)	(786,379)
Proceeds from cancellation of insurance funds	63,482	170,885
Other, net	83,983	86,341
Net cash provided by (used in) investing activities	(882,828)	(1,887,396)

	(Thousands of yen)	
	FY3/24	FY3/25
	(Apr. 1, 2023 - Mar. 31, 2024)	(Apr. 1, 2024 - Mar. 31, 2025)
Cash flows from financing activities		
Proceeds from long-term borrowings	—	1,211,000
Repayments of long-term borrowings	—	(17,343)
Purchase of treasury shares	(287)	(701,291)
Proceeds from disposal of treasury shares	—	710,706
Proceeds from sale of shares of subsidiaries not resulting in change in scope of consolidation	—	234,034
Dividends paid	(970,733)	(687,703)
Dividends paid to non-controlling interests	—	(71,558)
Purchase of treasury shares of subsidiaries	—	(94,038)
Other, net	(27,163)	(31,225)
Net cash provided by (used in) financing activities	(998,184)	552,580
Effect of exchange rate change on cash and cash equivalents	70,545	94,855
Net increase (decrease) in cash and cash equivalents	1,163,162	1,435,397
Cash and cash equivalents at beginning of period	12,795,930	13,959,093
Cash and cash equivalents at end of period	13,959,093	15,394,490



**(5) Notes to Consolidated Financial Statements****Assumption for Going Concern**

Not applicable.

**Business Combinations**

(Transactions, etc. under common control)

At a meeting of the Board of Directors held on November 30, 2024, the Company resolved to carry out an absorption-type merger between Trim Medical Holdings Inc., a wholly owned subsidiary of the Company, and the Company as the surviving company. The absorption-type merger was carried out on February 1, 2025.

**(1) Overview of transactions****1) Names and business descriptions of the companies involved**

Name of combining company: NIHON TRIM CO., LTD.

Business description: Sales of health-related equipment centered on EHW apparatus and related accessories

Name of combined company: Trim Medical Holdings Inc.

Business description: Management and operation of subsidiaries engaged in advanced medical businesses

**2) Date of business combination**

February 1, 2025

**3) Legal form of business combination**

An absorption-type merger with the Company as the surviving company, in which Trim Medical Holdings Inc. dissolved

**4) Name of company after combination**

NIHON TRIM CO., LTD.

**5) Other matters concerning overview of transactions**

The absorption-type merger was carried out to further improve the efficiency of administrative operations within the Group.

**(2) Overview of accounting treatment performed**

The transaction has been accounted for as a transaction under common control in accordance with the “Accounting Standard for Business Combinations” (ASBJ Statement No. 21, January 16, 2019) and the “Implementation Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures” (ASBJ Guidance No. 10, January 16, 2019).

**Segment and Other Information**

(Segment information)

**1. Overview of reportable segment**

The Group’s reportable segment is a component for which discrete financial information is available and which is regularly reviewed by the Group’s highest decision-making body in order to determine management resources to be allocated to the segment and assess its performance.

There are two reportable operating segments: the water healthcare business and the medical business.

The water healthcare business includes EHW apparatus sales and associated operations. The medical business includes business operations in the fields of medical and preventive healthcare and regenerative medicine.

**2. Calculation methods for net sales, profit or loss, assets, liabilities, and other items of each reportable segment**

The accounting method used for reportable operating segments is generally the same as the methods adopted in the preparation of consolidated financial statements.

Profits for reportable segments are operating profit figures.

3. Information related to net sales, profit or loss, assets, liabilities and other items of each reportable segment  
FY3/24 (Apr. 1, 2023 - Mar. 31, 2024)

	Reportable segment			Adjustments	(Thousands of yen) Amounts recorded in consolidated financial statements(Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	17,777,955	2,636,909	20,414,865	—	20,414,865
Inter-segment net sales and transfers	—	—	—	—	—
Total	17,777,955	2,636,909	20,414,865	—	20,414,865
Segment profit	2,688,103	392,383	3,080,486	—	3,080,486
Segment assets	22,905,605	7,216,513	30,122,119	1,422,641	31,544,761
Other items					
Depreciation	305,212	120,777	425,989	14,436	440,426
Increase in property, plant and equipment and intangible assets	280,593	147,819	428,412	—	428,412

Note: The segment profit subtotal is consistent with the operating profit of the consolidated statement of income.

FY3/25 (Apr. 1, 2024 - Mar. 31, 2025)

	Reportable segment			Adjustments	(Thousands of yen) Amounts recorded in consolidated financial statements(Note)
	Water Healthcare	Medical	Subtotal		
Net sales					
Net sales to external customers	19,565,707	2,898,123	22,463,830	—	22,463,830
Inter-segment net sales and transfers	—	—	—	—	—
Total	19,565,707	2,898,123	22,463,830	—	22,463,830
Segment profit	2,895,811	389,825	3,285,636	—	3,285,636
Segment assets	25,894,625	8,040,143	33,934,768	1,419,011	35,353,779
Other items					
Depreciation	329,349	127,102	456,452	14,994	471,446
Increase in property, plant and equipment and intangible assets	353,441	710,157	1,063,599	—	1,063,599

Note: The segment profit subtotal is consistent with the operating profit of the consolidated statement of income.

**Per Share Information**

(Yen)

	FY3/24 (Apr. 1, 2023 - Mar. 31, 2024)	FY3/25 (Apr. 1, 2024 - Mar. 31, 2025)
Net assets per share	2,911.21	3,125.80
Net income per share	280.51	292.41

- Notes: 1. Diluted net income per share is not presented since the Company has no outstanding dilutive securities.
2. The following is a reconciliation of net income per share.
3. For the purpose of calculating net assets per share, the number of shares of the Company held by Custody Bank of Japan, Ltd. (Trust Account E) as trust assets for Employee Stock Ownership Plan (J-ESOP) was included in the number of treasury shares, which was to be deducted from the total number of shares issued at end of period (432,900 shares as of March 31, 2024 and 432,900 shares as of March 31, 2025). In addition, for the purpose of calculating net income per share, the number of shares of the Company held as trust assets was included in the number of treasury shares, which was to be deducted from the calculation of the average number of shares outstanding during the period (432,900 shares as of March 31, 2024 and 432,900 shares as of March 31, 2025).
4. For the purpose of calculating net assets per share, the number of shares of the Company held by The Nomura Trust & Banking Co., Ltd. (Nihon Trim Employee Shareholding Association Dedicated Trust Account) as trust assets for the Trust-Type Employee Shareholding Incentive Plan (E-Ship) was included in the number of treasury shares, which was to be deducted from the total number of shares issued at end of period (187,100 shares as of March 31, 2025). In addition, for the purpose of calculating net income per share, the number of shares of the Company held as trust assets was included in the number of treasury shares, which was to be deducted from the calculation of the average number of shares outstanding during the period (42,370 shares as of March 31, 2025).

	FY3/24 (Apr. 1, 2023 - Mar. 31, 2024)	FY3/25 (Apr. 1, 2024 - Mar. 31, 2025)
Net income per share		
Profit attributable to owners of parent (thousands of yen)	2,150,143	2,241,402
Profit not attributable to common shareholders (thousands of yen)	—	—
Profit attributable to common shareholders of parent (thousands of yen)	2,150,143	2,241,402
Average number of common shares outstanding during the period (shares)	7,665,091	7,665,202

**Subsequent Events**

Not applicable.

*This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.*